Since it is known that some cancer-related genes and proteins are difficult to target with small molecules, for example the p53 gene, drugs targeting an edge/interaction for which such genes are connected may offer ways of indirectly targeting and influencing those genes (Arkin and Wells, 2004). Here, TP53 is linked to cancer.